Avenues to Precision Oncology
Until recently, the clinical management of cancer heavily relied on anatomical and histopathological criteria, with *ad hoc* guidelines directing the therapeutic choices in specific indications. In the last years, the development and therapeutic implementation of novel anticancer therapies significa...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
THE HEALTHBOOK COMPANY LTD.
2020-03-01
|
| Series: | healthbook TIMES. Oncology Hematology |
| Online Access: | https://doi.org/10.36000/hbT.OH.2020.03.013 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846126522615726080 |
|---|---|
| author | Alexander Meisel |
| author_facet | Alexander Meisel |
| author_sort | Alexander Meisel |
| collection | DOAJ |
| description | Until recently, the clinical management of cancer heavily relied on anatomical and histopathological criteria, with *ad hoc* guidelines directing the therapeutic choices in specific indications. In the last years, the development and therapeutic implementation of novel anticancer therapies significantly improved the clinical outcome of cancer patients. Nonetheless, such cutting-edge approaches revealed the limitation of the one-size-fits-all paradigm. The newly discovered molecular targets can be exploited either as *bona fide* targets for subsequent drug development, or as tools to precision medicine, in the form of prognostic and/or predictive biomarkers. This article provides an overview of some of the most recent advances in precision medicine in oncology, with a focus on novel tissue-agnostic anticancer therapies. The definition and implementation of biomarkers and companion diagnostics in clinical trials and clinical practice are also discussed, as well as the changing landscape in clinical trial design. |
| format | Article |
| id | doaj-art-ad06a46ea2094f4fb4becc08b54ed898 |
| institution | Kabale University |
| issn | 2673-2106 |
| language | English |
| publishDate | 2020-03-01 |
| publisher | THE HEALTHBOOK COMPANY LTD. |
| record_format | Article |
| series | healthbook TIMES. Oncology Hematology |
| spelling | doaj-art-ad06a46ea2094f4fb4becc08b54ed8982024-12-12T17:11:17ZengTHE HEALTHBOOK COMPANY LTD.healthbook TIMES. Oncology Hematology2673-21062020-03-0131Avenues to Precision OncologyAlexander MeiselUntil recently, the clinical management of cancer heavily relied on anatomical and histopathological criteria, with *ad hoc* guidelines directing the therapeutic choices in specific indications. In the last years, the development and therapeutic implementation of novel anticancer therapies significantly improved the clinical outcome of cancer patients. Nonetheless, such cutting-edge approaches revealed the limitation of the one-size-fits-all paradigm. The newly discovered molecular targets can be exploited either as *bona fide* targets for subsequent drug development, or as tools to precision medicine, in the form of prognostic and/or predictive biomarkers. This article provides an overview of some of the most recent advances in precision medicine in oncology, with a focus on novel tissue-agnostic anticancer therapies. The definition and implementation of biomarkers and companion diagnostics in clinical trials and clinical practice are also discussed, as well as the changing landscape in clinical trial design.https://doi.org/10.36000/hbT.OH.2020.03.013 |
| spellingShingle | Alexander Meisel Avenues to Precision Oncology healthbook TIMES. Oncology Hematology |
| title | Avenues to Precision Oncology |
| title_full | Avenues to Precision Oncology |
| title_fullStr | Avenues to Precision Oncology |
| title_full_unstemmed | Avenues to Precision Oncology |
| title_short | Avenues to Precision Oncology |
| title_sort | avenues to precision oncology |
| url | https://doi.org/10.36000/hbT.OH.2020.03.013 |
| work_keys_str_mv | AT alexandermeisel avenuestoprecisiononcology |